Expert Q&A: Labs Must Take a Greater Role in Guiding Clinicians About Abnormal Data
Lee Fleisher, MD, advocates for clearer interpretation of test results by medical laboratory scientists
Keep up to date on the latest legal, compliance, and business developments affecting the lab industry, while offering analysis and insight to ensure your lab’s success.
Lee Fleisher, MD, advocates for clearer interpretation of test results by medical laboratory scientists
On March 28, the 118th Congress raised lab industry hopes once more by reintroducing the Saving Access to Laboratory Services Act (SALSA).
A new OIG Advisory Opinion sheds some light on when it’s permissible for a lab to offer customers a gift card for returning their at-home testing kit.
It’s not just billions of dollars on the line, but the very future of whistleblower lawsuits and FCA enforcement.
The DOJ’s recent report on FCA enforcement statistics for FY 2022 shows that while actions are dramatically up, recoveries are way down.
No company better embodies the vicissitudes of running a COVID-19-focused diagnostics business during the pandemic period than Lucira Health.
HHS secretary takes action to ensure that EUAs remain in effect until the “significant potential” for a COVID-19 PHE no longer exists.
Product integration collaborations have become increasingly common, with five such deals being announced between February and mid-March.
While only time will tell how bad the ultimate damage turns out to be, it appears for now at least that the industry has dodged a bullet.
Carl Icahn has decided to take his beef with Illumina’s board of directors over the acquisition directly to company shareholders.
Agency’s annual report to Congress concludes that providers are doing just fine and don’t need a big bump in pay at this time.